Annual EBITDA
-$150.11 M
+$26.24 M+14.88%
31 December 2023
Summary:
Esperion Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$150.11 million, with the most recent change of +$26.24 million (+14.88%) on 31 December 2023. During the last 3 years, it has fallen by -$29.77 million (-24.74%). ESPR annual EBITDA is now -1391.88% below its all-time high of -$10.06 million, reached on 31 December 2011.ESPR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$14.42 M
+$33.78 M+70.09%
30 September 2024
Summary:
Esperion Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$14.42 million, with the most recent change of +$33.78 million (+70.09%) on 30 September 2024. Over the past year, it has increased by +$11.81 million (+45.04%). ESPR quarterly EBITDA is now -111.14% below its all-time high of $129.37 million, reached on 30 June 2020.ESPR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$28.84 M
+$11.81 M+29.06%
30 September 2024
Summary:
Esperion Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$28.84 million, with the most recent change of +$11.81 million (+29.06%) on 30 September 2024. Over the past year, it has increased by +$121.05 million (+80.76%). ESPR TTM EBITDA is now -1240.47% below its all-time high of -$2.15 million, reached on 31 March 2012.ESPR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ESPR EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.9% | +45.0% | +80.8% |
| 3 y3 years | -24.7% | +74.1% | +89.2% |
| 5 y5 years | +25.5% | +77.6% | +68.3% |
ESPR EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -24.7% | +32.4% | -119.2% | +74.1% | -3.7% | +89.2% |
| 5 y | 5 years | -69.2% | +32.4% | -111.1% | +84.9% | -3.7% | +90.1% |
| alltime | all time | -1391.9% | +32.4% | -111.1% | +84.9% | -1240.5% | +90.1% |
Esperion Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$14.42 M(-70.1%) | -$28.84 M(-29.1%) |
| June 2024 | - | -$48.19 M(-164.2%) | -$40.66 M(+46.2%) |
| Mar 2024 | - | $75.05 M(-281.8%) | -$27.81 M(-81.5%) |
| Dec 2023 | -$150.11 M(-14.9%) | -$41.28 M(+57.4%) | -$150.11 M(+0.1%) |
| Sept 2023 | - | -$26.23 M(-25.8%) | -$149.89 M(-8.9%) |
| June 2023 | - | -$35.35 M(-25.2%) | -$164.52 M(-9.1%) |
| Mar 2023 | - | -$47.25 M(+15.1%) | -$181.08 M(+2.7%) |
| Dec 2022 | -$176.35 M(-20.6%) | -$41.07 M(+0.5%) | -$176.35 M(-5.6%) |
| Sept 2022 | - | -$40.86 M(-21.3%) | -$186.82 M(-7.3%) |
| June 2022 | - | -$51.91 M(+22.1%) | -$201.54 M(+10.7%) |
| Mar 2022 | - | -$42.52 M(-17.5%) | -$182.00 M(-18.1%) |
| Dec 2021 | -$222.14 M(+84.6%) | -$51.54 M(-7.3%) | -$222.14 M(-16.5%) |
| Sept 2021 | - | -$55.58 M(+71.7%) | -$265.99 M(-8.5%) |
| June 2021 | - | -$32.37 M(-60.8%) | -$290.76 M(+125.4%) |
| Mar 2021 | - | -$82.66 M(-13.3%) | -$129.02 M(+7.2%) |
| Dec 2020 | -$120.33 M(+35.6%) | -$95.39 M(+18.7%) | -$120.33 M(+45.6%) |
| Sept 2020 | - | -$80.35 M(-162.1%) | -$82.67 M(+24.1%) |
| June 2020 | - | $129.37 M(-274.9%) | -$66.61 M(-73.4%) |
| Mar 2020 | - | -$73.97 M(+28.2%) | -$250.15 M(+181.9%) |
| Dec 2019 | -$88.73 M(-56.0%) | -$57.72 M(-10.2%) | -$88.73 M(-2.5%) |
| Sept 2019 | - | -$64.29 M(+18.7%) | -$90.97 M(+18.9%) |
| June 2019 | - | -$54.17 M(-161.9%) | -$76.53 M(+11.3%) |
| Mar 2019 | - | $87.45 M(-245.8%) | -$68.78 M(-66.1%) |
| Dec 2018 | -$201.52 M(+21.0%) | -$59.97 M(+20.3%) | -$203.06 M(+13.1%) |
| Sept 2018 | - | -$49.84 M(+7.4%) | -$179.54 M(+2.4%) |
| June 2018 | - | -$46.42 M(-0.9%) | -$175.37 M(+1.6%) |
| Mar 2018 | - | -$46.83 M(+28.5%) | -$172.54 M(+3.6%) |
| Dec 2017 | -$166.53 M | -$36.44 M(-20.2%) | -$166.53 M(+4.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2017 | - | -$45.67 M(+4.8%) | -$158.88 M(+21.8%) |
| June 2017 | - | -$43.59 M(+6.8%) | -$130.46 M(+29.5%) |
| Mar 2017 | - | -$40.82 M(+41.8%) | -$100.73 M(+35.5%) |
| Dec 2016 | -$74.33 M(+51.6%) | -$28.79 M(+66.9%) | -$74.33 M(+27.1%) |
| Sept 2016 | - | -$17.25 M(+24.3%) | -$58.47 M(+8.6%) |
| June 2016 | - | -$13.87 M(-3.7%) | -$53.84 M(+3.2%) |
| Mar 2016 | - | -$14.41 M(+11.4%) | -$52.17 M(+6.4%) |
| Dec 2015 | -$49.03 M(+36.4%) | -$12.93 M(+2.5%) | -$49.03 M(+8.1%) |
| Sept 2015 | - | -$12.62 M(+3.4%) | -$45.36 M(+7.1%) |
| June 2015 | - | -$12.20 M(+8.3%) | -$42.36 M(+7.6%) |
| Mar 2015 | - | -$11.27 M(+21.6%) | -$39.36 M(+9.5%) |
| Dec 2014 | -$35.95 M(+43.3%) | -$9.27 M(-3.7%) | -$35.95 M(-1.1%) |
| Sept 2014 | - | -$9.62 M(+4.6%) | -$36.36 M(+13.7%) |
| June 2014 | - | -$9.20 M(+17.0%) | -$31.96 M(+8.1%) |
| Mar 2014 | - | -$7.86 M(-18.8%) | -$29.56 M(+17.9%) |
| Dec 2013 | -$25.08 M(+147.9%) | -$9.68 M(+85.2%) | -$25.08 M(+42.6%) |
| Sept 2013 | - | -$5.23 M(-23.1%) | -$17.58 M(+14.8%) |
| June 2013 | - | -$6.80 M(+101.1%) | -$15.31 M(+35.0%) |
| Mar 2013 | - | -$3.38 M(+54.8%) | -$11.34 M(+12.1%) |
| Dec 2012 | -$10.12 M(+0.5%) | -$2.18 M(-26.1%) | -$10.12 M(+27.5%) |
| Sept 2012 | - | -$2.95 M(+4.5%) | -$7.93 M(+59.3%) |
| June 2012 | - | -$2.83 M(+31.4%) | -$4.98 M(+131.4%) |
| Mar 2012 | - | -$2.15 M | -$2.15 M |
| Dec 2011 | -$10.06 M(-64.0%) | - | - |
| Dec 2002 | -$27.95 M(+5.5%) | - | - |
| Dec 2001 | -$26.48 M(+3.7%) | - | - |
| Dec 2000 | -$25.52 M(+118.4%) | - | - |
| Dec 1999 | -$11.68 M | - | - |
FAQ
- What is Esperion Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Esperion Therapeutics?
- What is Esperion Therapeutics annual EBITDA year-on-year change?
- What is Esperion Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Esperion Therapeutics?
- What is Esperion Therapeutics quarterly EBITDA year-on-year change?
- What is Esperion Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Esperion Therapeutics?
- What is Esperion Therapeutics TTM EBITDA year-on-year change?
What is Esperion Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ESPR is -$150.11 M
What is the all time high annual EBITDA for Esperion Therapeutics?
Esperion Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$10.06 M
What is Esperion Therapeutics annual EBITDA year-on-year change?
Over the past year, ESPR annual earnings before interest, taxes, depreciation & amortization has changed by +$26.24 M (+14.88%)
What is Esperion Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ESPR is -$14.42 M
What is the all time high quarterly EBITDA for Esperion Therapeutics?
Esperion Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $129.37 M
What is Esperion Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ESPR quarterly earnings before interest, taxes, depreciation & amortization has changed by +$11.81 M (+45.04%)
What is Esperion Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ESPR is -$28.84 M
What is the all time high TTM EBITDA for Esperion Therapeutics?
Esperion Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.15 M
What is Esperion Therapeutics TTM EBITDA year-on-year change?
Over the past year, ESPR TTM earnings before interest, taxes, depreciation & amortization has changed by +$121.05 M (+80.76%)